Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models

International Journal of Cancer

Volumn 83, Issue 1, 1999, Pages 127-134

  Endo, Mika ^a   Shinbori, Noriko ^a   Fukase, Yu ^a   Sawada, Noriaki ^a   Ishikawa, Tohru ^a   Ishitsuka, Hideo ^a   Tanaka, Yutaka ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CREMOPHOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE PHOSPHORYLASE; UFT; URIDINE PHOSPHORYLASE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOXURIDINE; HUMANS; KINETICS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; THYMIDINE PHOSPHORYLASE; TIME FACTORS; UP-REGULATION;

EID: 0032856558     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990924)83:1<127::AID-IJC22>3.0.CO;2-6     Document Type: Article

References (26)

1. ARASAKI, M., ISHITSUKA, H., KURUMA, I., MIWA, M., MURASAKI, C., SHIMMA, N. and UMEDA, I., N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines. Europ. Patent Appl. 92121538.0 (1992).
2. BLUM, J.L., BUZDAR, A.U., LO RUSSO, P.M., KUTER, I., VOGEL, C., BURGER, H.U., BROWN, C. and GRIFFIN, T., A mullicenter phase II trial of Xeloda® (capecitabine) in paclitaxel-refractory metastatic breast cancer (MBC). Proc. Amer. Soc. clin. Oncol., 17, 476 (1998).
3. BUDMAN, D.R., MEROPOL, N.J., REIGNER, B., CREAVEN, P.J., LICHTMAN, S.M., BERGHORN, E., BEHR, J., GORDON, R.J., OSTERWALDER, B. and GRIFFIN, T., Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. clin. Oncol., 16, 1795-1802 (1998).
4. BULL, J.M., TORMEY, D.C., LI, S.H., CARBONE, P.P., FALKSON, G., BLOM, J., PERLIN, E. and SIMON, R., A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer, 41, 1649-1657 (1978).
5. CANELLOS, G.P., POCOCK, S.J., TAYLOR, S.G., III, SEARS, M.E., KLAASEN, D.J. and BAND, P.R., Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with 1-phenylalanine mustard. Cancer, 38, 1882-1886 (1976).
6. CHAPPELL, W.R. and MORDENTI, J., Extrapolation of toxicological and pharmacological data from animals to humans. In: B. Testa (ed). Advances in drug research (Vol. 20), pp. 2-116, Academic Press, London (1991).
7. EDA, H., FUJIMOTO, K., WATANABE, S., ISHIKAWA, T., OHIWA, T., TATSUNO, K., TANAKA, Y. and ISHITSUKA, H., Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5'-deoxy-5-fluorouridine. Jpn. J. Cancer Res., 84, 341-347 (1993a).
8. EDA, H., FUJIMOTO, K., WATANABE, S., URA, M., HINO, A., TANAKA, Y., WADA, K. and ISHITSUKA, H., Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother. Pharm., 32, 333-338 (1993b).
9. EDA, H., HASEGAWA, M., TATSUNO, K., MATSUMOTO, T., WATANABE, S., UCHIDA, T. and ISHITSUKA, H., Characteristics of human colon cancer cells transfected with thymidine phosphorylase gene [in Japanese]. J. Jpn. Soc. Cancer Ther., 29, 164 (1994).
10. FOSSATI, R., CONFALONIERI, C., TORRI, V., GHISLANDI, E., PENNA, A., PISTOTTI, V., TINAZZI, A. and LIBERATI, A., Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. clin. Oncol., 16, 3439-3460 (1998).
11. GRIFFITHS, L., DACHS, G.U., BICKNELL, R., HARRIS, A.L. and STRATFORD, I.J., The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells growth in vitro and in vivo. Cancer Res., 57, 570-572 (1997).
12. HARAGUCHI, M., FURUKAWA, T., SUMIZAWA, T. and AKIYAMA, S., Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res., 53, 5680-5682 (1993).
13. ISHIKAWA, T., SEKIGUCHI, F., FUKASE, Y., SAWADA, N. and ISHITSUKA, H., Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res., 58, 685-690 (1998).
14. KONO, A., HARA, Y., SUGATA, S. KARUBE, Y., MATSUSHIMA, Y. and ISHITSUKA, H., Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase inhuman tumors. Chem. Pharm. Bull., 31, 175-178 (1983).
15. KOWALSKI, B.R. and BENDER, C.F., The application of pattern recognition to screening prospective anticancer drugs. Adenocarcinoma 755 biological activity test. J. Amer. chem. Soc., 96, 916-918 (1974).
16. LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. and RANDALL, R.J., Protein measurement with the Folin phenol reagent. J. biol. Chem., 193, 265-275 (1951).
17. MIWA, M., URA, M., NISHIDA, M., SAWADA, N., ISHIKAWA, T., MORI, K., SHIMMA, N., UMEDA, I. and ISHITSUKA, H., Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Europ. J. Cancer, 34, 1274-1281 (1998).
18. NIITANI, H. and 16 OTHERS, Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) on patients with malignant cancer. Multi-institutional cooperative study. Jpn. J. Cancer Chemother., 12, 2044-2051 (1985).
19. NINOMIYA, Y., MIWA, M., EDA, H., SAHARA, H., FUJIMOTO, K., ISHIDA, M., UMEDA, I., YOKOSE, K. and ISHITSUKA, H., Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine. Jpn. J. Cancer Res., 81, 188-195 (1990).
20. NISHIDA, M., HINO, A., MORI, K., MATSUMOTO, T., YOSHIKUBO, T. and ISHITSUKA, H., Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol. Pharm. Bull., 19, 1407-1411 (1996).
21. OVEJERA, A.A., HOUCHENS, D.P. and BARKER, A.D., Chemotherapy of human tumor xenografts in genetically athymic mice. Ann. clin. Lab. Sci., 8, 50-56 (1978).
22. SAWADA, N., ISHIKAWA, T., FUKASE, Y., NISHIDA, M., YOSHIKUBO, T. and ISHITSUKA, H., Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res., 4, 1013-1019 (1998).
23. SUZUKI, S., HONGU, Y., FUKAZAWA, H., ICHIHARA, S. and SHIMIZU, H., Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats. Gann, 71, 238-245 (1980).
24. 2a with 5'-deoxy-5-fluorouridine in colorectal cancer cells in vitro. Europ. J. Cancer, 28, 368-372 (1992).
25. VERBS, Z., SZABOLCS, A., SZINAI, I., DÉNES, G., KAJTÁR-PEREDY, M. and ÖTVÖS, L., 5-Substituted-2.2'-anhydrouridines, potent inhibitors of uridine phosphorylase. Biochem. Pharmacol., 34, 1737-1740 (1985).
26. YOSHIMOTO, M., TADA, T., SAITO, M., TAKAHASHI, K. and KASUMI, F., Treatment of metastatic breast cancer using a combination of two oral drugs of 5'-deoxy-5-fluorouridine and cyclophosphamide [in Japanese]. J. clin. exp. Med. (IGAKU NO AYUMI), 184, 1013-1014 (1998).